Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Lantern Pharma (LTRN) and OmniAb (OABI)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on ALX Oncology Holdings (ALXO – Research Report), Lantern Pharma (LTRN – Research Report) and OmniAb (OABI – Research Report).

ALX Oncology Holdings (ALXO)

H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on ALX Oncology Holdings today and set a price target of $25.00. The company’s shares closed last Thursday at $16.95, close to its 52-week high of $17.83.

According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 6.2% and a 37.8% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as ImmunoPrecise Antibodies, Janux Therapeutics Inc, and Corcept Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for ALX Oncology Holdings with a $20.80 average price target.

See the top stocks recommended by analysts >>

Lantern Pharma (LTRN)

H.C. Wainwright analyst Emily Bodnar maintained a Hold rating on Lantern Pharma today. The company’s shares closed last Thursday at $6.81.

According to TipRanks.com, Bodnar is a 3-star analyst with an average return of 4.7% and a 34.7% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Connect Biopharma Holdings, Acrivon Therapeutics, Inc., and TransCode Therapeutics.

Lantern Pharma has an analyst consensus of Hold.

OmniAb (OABI)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on OmniAb today and set a price target of $11.00. The company’s shares closed last Thursday at $4.57.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 12.5% and a 41.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Cadrenal Therapeutics, Inc., and Actinium Pharmaceuticals.

OmniAb has an analyst consensus of Strong Buy, with a price target consensus of $9.67, an 113.0% upside from current levels. In a report issued on April 29, RBC Capital also maintained a Buy rating on the stock with a $7.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALXO:

• ALX Oncology Appoints Allison Dillon as Chief Business Officer
• ALX Oncology appoints Dillon as Chief Business Officer
• ALX Oncology Board Reshuffles Following Director Resignations
• ALX Oncology announces initiation of Phase 2 trial in patients with HPVOC
• ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting